One To Watch
Vogenx
Company Overview
A clinical-stage North Carolina biotech developing mizagliflozin, a first-in-class oral SGLT1 inhibitor, for post-bariatric hypoglycemia, gastroparesis, and GIP-dependent Cushing's syndrome, with a Nasdaq IPO filed in July 2026. Vogenx targets serious metabolic and gastrointestinal diseases where no approved pharmacological options exist. The company has built a two-asset pipeline around a licensed small molecule and a preclinical weight-maintenance candidate.
Headquarters and Global Presence
Vogenx is headquartered in Raleigh, North Carolina. The company is pre-revenue and lean, reporting just four full-time and one part-time employee as of May 2026. Its licensed rights to mizagliflozin cover worldwide commercialization excluding Japan, Korea, and Taiwan.
Founding and History
Vogenx was founded in 2021 by a team of industry veterans with experience in endocrine drug development. In the same year, it secured an exclusive worldwide licensing deal with Japan's Kissei Pharmaceutical for mizagliflozin outside Japan, Korea, and Taiwan. Since inception the company raised approximately $11.5 million, including an $11 million Series A financing. On 15 July 2026, it filed for a Nasdaq Capital Market IPO under the ticker VOGX, proposing to sell 6.25 million shares at $11 to $13 apiece, targeting net proceeds of approximately $67.8 million at the midpoint.
Therapy Areas and Focus
Vogenx focuses on metabolic and gastrointestinal diseases with limited or no approved therapies. Post-bariatric hypoglycemia is a debilitating condition affecting patients who have undergone bariatric surgery, causing dangerous drops in blood glucose. Gastroparesis is a chronic gastric motility disorder, and GIP-dependent Cushing's syndrome is a rare endocrine condition causing pathologically elevated cortisol. All three share a common thread: aberrant glucose and insulin signaling where SGLT1 inhibition offers a mechanistically grounded intervention.
Technology Platforms and Modalities
Mizagliflozin is an oral small molecule that selectively inhibits SGLT1, the sodium-dependent glucose transporter in the gastrointestinal tract responsible for moving dietary glucose into the bloodstream. By blocking SGLT1, mizagliflozin reduces intestinal glucose absorption and attenuates the exaggerated insulin secretion that drives post-bariatric hypoglycemia. The gut-targeted mechanism distinguishes it from SGLT2 inhibitors, which act on the kidney and dominate the broader diabetes market. Preclinical candidate VGX-2857 targets weight maintenance after substantial weight loss, extending the metabolic rationale into the obesity adjacency.
Key Pipeline and Programs
Mizagliflozin is the lead asset, an oral SGLT1 inhibitor studied in over 500 subjects across 10 clinical trials. In post-bariatric hypoglycemia, two Phase II studies have reported positive results. Study VGX 001-011 (results announced June 2023) showed a mean glucose nadir improvement of 12.6 mg/dL (p=0.045) and a mean peak glucose change of -29 mg/dL (p=0.027) versus baseline in a randomized, sequential crossover design. Study VGX 001-012 (results announced June 2024) demonstrated significant reductions in Level 3 hypoglycemia events of -0.27 per day at the 5 mg dose (p=0.023) versus placebo. A Phase IIb trial in post-bariatric hypoglycemia is planned to begin in 2026, and a Phase II gastroparesis trial is expected to launch in 2027. Mizagliflozin is also being pursued for GIP-dependent Cushing's syndrome, a rare cortisol-excess condition with no approved targeted therapy.
VGX-2857 is a preclinical-stage candidate being evaluated for metabolic diseases, specifically weight maintenance following substantial weight loss. No clinical timeline has been disclosed.
Recent Developments
Vogenx filed its Nasdaq Capital Market IPO registration on 15 July 2026, with JonesTrading Institutional Services as lead underwriter. The proposed offering of 6.25 million shares at $11 to $13 per share would net approximately $67.8 million at the midpoint, and the company expects proceeds to extend its operating runway through approximately 2028. The IPO proceeds are earmarked primarily for the Phase IIb post-bariatric hypoglycemia program and the planned gastroparesis study.
Key Personnel
James Green serves as chairman, president, and chief executive officer. He brings more than 25 years of pharmaceutical leadership experience and was previously chief executive of both Avolynt and BHV Pharma.
Strategic Partnerships
Vogenx's defining deal is its 2021 exclusive license from Kissei Pharmaceutical, a Japanese company, granting worldwide rights to mizagliflozin outside Japan, Korea, and Taiwan. Kissei retains commercial rights in those three territories. No additional partnerships or collaborations have been disclosed.
FAQ Section
Vogenx filed its Nasdaq IPO on 15 July 2026, targeting net proceeds of approximately $67.8 million at the midpoint of a $11 to $13 per share range. The primary use of proceeds is advancing mizagliflozin through a Phase IIb trial in post-bariatric hypoglycemia and initiating a Phase II gastroparesis study in 2027. The company expects this funding to carry it through approximately 2028, giving it a roughly two-year runway to generate clinical catalysts.
Post-bariatric hypoglycemia is driven by accelerated gastric emptying and exaggerated incretin responses after bariatric surgery, which cause a surge in insulin secretion disproportionate to glucose intake. SGLT1 in the gut wall is the primary transporter that moves dietary glucose into the portal circulation, and blocking it dampens both the glucose spike and the secondary insulin overshoot. Mizagliflozin's two Phase II studies showed statistically significant reductions in glucose nadir changes and in severe Level 3 hypoglycemia events versus placebo, providing clinical validation of the mechanism.
Approved SGLT2 inhibitors such as dapagliflozin and empagliflozin act on the kidney to promote urinary glucose excretion, and are approved for type 2 diabetes, heart failure, and chronic kidney disease. Mizagliflozin targets SGLT1 in the gastrointestinal tract, modulating glucose absorption at the point of entry into the body rather than at the point of renal reabsorption. This gut-selective mechanism is relevant to conditions defined by exaggerated postprandial insulin responses, a profile that kidney-targeted SGLT2 inhibitors do not address.
Mizagliflozin has completed two Phase II studies in post-bariatric hypoglycemia, both reporting statistically significant improvements in glucose and hypoglycemia endpoints. The company is advancing to a Phase IIb trial, planned to start in 2026, which will be the next pivotal data readout. A separate Phase II study in gastroparesis is planned for 2027, and development in GIP-dependent Cushing's syndrome is also underway, broadening the clinical risk profile across three indications.
Gastroparesis is a chronic gastric motility disorder affecting gastric emptying, where SGLT1 modulation of gut glucose signaling may offer symptomatic benefit. GIP-dependent Cushing's syndrome is a rare endocrine condition in which cortisol rises pathologically in response to GIP, a gut hormone; the connection to intestinal glucose transport makes mizagliflozin a mechanistically relevant candidate. Preclinical asset VGX-2857 targets weight maintenance after substantial weight loss, an area of growing commercial interest in the context of GLP-1-driven obesity treatment.
Vogenx is pre-revenue and operated with just four full-time employees as of May 2026, reporting a net loss of $1.446 million in 2025. Since founding in 2021 it raised approximately $11.5 million in private capital before the IPO filing. The IPO, if completed, would represent a step-change in its capitalization, with proceeds expected to fund operations through 2028 and support two mid-stage clinical programs.
The key watchpoints for Vogenx are:
- Completion of the Nasdaq IPO at a valuation that adequately funds the Phase IIb post-bariatric hypoglycemia program through data readout.
- Phase IIb results in post-bariatric hypoglycemia, which will set the clinical credibility of mizagliflozin and the path toward Phase III.
- Initiation and initial data from the Phase II gastroparesis trial, planned for 2027, which opens a second commercial opportunity.
- Reliance on a single licensed asset from Kissei Pharmaceutical means any regulatory, supply, or licensing complication flows directly to pipeline continuity.
- The company's minimal headcount and pre-revenue status leave limited operational buffer if clinical timelines or the IPO process extend beyond plan.
Today's issue
| Headless Content Management with Blaze